Ovarian function after surgical treatment for cervical cancer.
OBJECTIVE
Our previous analysis found a high rate of early menopause in cervical cancer patients with ovarian transposition (OT) compared to a group that underwent radical hysterectomy (RH) alone. The current study evaluates ovarian function in the same group for a prolonged follow-up period and analyzes predictive factors for early menopause.


METHODS
One hundred two cervical cancer patients were treated with RH and/or lymphadenectomy and ovarian preservation from 1982 to 1989. A retrospective chart review was conducted, followed by a survey to determine the time of menopause.


RESULTS
Eighty-three patients underwent RH and 19 patients underwent a staging laparotomy. Eighty procedures included OT. Twenty-six patients received postoperative radiation therapy. The mean follow-up for premenopausal patients was 87.0 months. The average age of menopause for the 13 nonradiated patients without unilateral oophorectomy (UO) or OT was 50.6 years. After OT without radiation therapy, 98.0% of patients retained ovarian function for a mean of 126 months with menopause at a mean of 45.8 years. When OT and radiation therapy were added, 41% retained ovarian function for a mean of 43 months and a mean age at menopause of 36.6 years. A multivariate analysis of nonradiated patients correlated age at diagnosis and a combination of OT procedure and UO with earlier ovarian failure.


CONCLUSIONS
RH with bilateral ovarian preservation and without OT does not significantly reduce the age of menopause. The addition of UO or OT to this treatment reduces ovarian function appreciably. The addition of radiation therapy after OT dramatically shortens ovarian function.
Buekers
T E
TE
Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA.
Anderson
B
B
Sorosky
J I
JI
Buller
R E
RE
D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D008593:Menopause; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D010053:Ovary / Q000503:physiopathology* / Q000528:radiation effects / Q000601:surgery; D016016:Proportional Hazards Models; D011835:Radiation Protection; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D012189:Retrospective Studies; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000503:physiopathology* / Q000532:radiotherapy / Q000601:surgery*